Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab Starts China Trial of Ulcerative Colitis Treatment

publication date: Oct 12, 2018

I-Mab Biopharma of Shanghai reported the first patient has been dosed in a China Phase II trial of TJ301 in patients with ulcerative colitis. I-Mab in-licensed China rights to the candidate from Switzerland's Ferring in late 2016. TJ301 is a selective IL-6 blocker that allows IL-6 to continue responding to infections, while it moderates the UC immune response. Because of its selective blocking mechanism, TJ301 is expected to show a better safety profile than its competitors. I-Mab has rights to the candidate in greater China and Korea. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital